Monitoring Patients With RET-Positive NSCLC

Author(s):

Heather A. Wakelee, MD, FASCO,Jacob Sands, MD

Panelists discuss how to monitor patients for response to treatment and early signs of resistance in RET fusion–positive non–small cell lung cancer (NSCLC), including the approach to follow-up molecular testing, and describe strategies for treatment sequencing after disease progression on RET inhibitors.

EP: 1.Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP: 2.Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP: 3.Testing Methodologies and Standards in Metastatic NSCLC

EP: 4.Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

EP: 5.Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

EP: 6.Initial Approach to Management of RET-Positive NSCLC

EP: 7.Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

EP: 8.Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

EP: 9.Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

EP: 10.Managing RET Inhibitor Treatment-Related Adverse Events

Now Viewing

EP: 11.Monitoring Patients With RET-Positive NSCLC

Dr Sands to Dr Wakelee: How do you monitor patients for response to treatment and early signs of resistance?
1. What is your approach to follow-up molecular testing?
Dr Wakelee: Describe your approach to treatment sequencing after disease progression on RET inhibitors.